Patents by Inventor Peter L. Turecek

Peter L. Turecek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20230130866
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: December 23, 2022
    Publication date: April 27, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMAPANY LIMITED
    Inventors: Peter MATTHIESSEN, Peter L. TURECEK, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 11564979
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: January 31, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20200376098
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: July 21, 2020
    Publication date: December 3, 2020
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter MATTHIESSEN, Peter L. TURECEK, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 10758599
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 1, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20190247475
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 15, 2019
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 10238720
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 26, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20180207245
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 26, 2018
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 9937244
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 10, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20170112906
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 9572778
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: February 21, 2017
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20160375111
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: May 3, 2016
    Publication date: December 29, 2016
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 9351935
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 31, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20140178357
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: November 22, 2013
    Publication date: June 26, 2014
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 8623352
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: January 7, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
    Publication number: 20110229455
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Application
    Filed: September 21, 2010
    Publication date: September 22, 2011
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz